top of page
BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations
Date: August 19, 2025 PMID: 10.1007/s43441-025-00860-5 Category: N/A Authors: Xiaohan Chi, Ying Yuan, Ruitao Lin Abstract: 40830695 Background: Personalized cancer treatment using combination therapies offers substantial therapeutic benefits over single-agent treatments in most cancers. However, unmet clinical needs and increasing market competition pressure drug developers to quickly optimize combination doses and clearly demonstrate the contribution of each component when d
bgtaylor1
Nov 11, 20252 min read
PoweREST: Statistical power estimation for spatial transcriptomics experiments to detect differentially expressed genes between two conditions
Date: July 29. 2025 PMID: PMC12316394 Category: N/A Authors: Lan Shui, Anirban Maitra, Ying Yuan, Ken Lau, Harsimran Kaur, Liang Li, Ziyi Li; Translational and Basic Science Research in Early Lesions Research Consortia Abstract: 40729405 Recent advancements in spatial transcriptomics (ST) have significantly enhanced biological research in various domains. However, the high cost for current ST data generation techniques restricts the large-scale application of ST. Consequently
bgtaylor1
Nov 11, 20252 min read
Expanded Performance Comparison of the Oncuria 10-Plex Bladder Cancer Urine Assay Using Three Different Luminex xMAP Instruments
Date: July 10, 2025 PMID: PMC12294033 Category: N/A Authors: Sunao Tanaka, Takuto Shimizu, Ian Pagano, Wayne Hogrefe, Sherry Dunbar, Charles J Rosser, Hideki Furuya Abstract: 40722499 Background/Objectives : The clinically validated multiplex Oncuria bladder cancer (BC) assay quickly and noninvasively identifies disease risk and tracks treatment success by simultaneously profiling 10 protein biomarkers in voided urine samples. Oncuria uses paramagnetic bead-based fluorescence
bgtaylor1
Nov 11, 20252 min read
bottom of page